The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://jesseugwh050185.weblogco.com/40430001/premium-investor-pharma-a-speculative-investment